Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Partners with TGen to Develop CGH Arrays for Cancer Research

NEW YORK, June 8 (GenomeWeb News) - Agilent Technologies and the Translational Genomics Research Institute have begun a collaboration to develop microarrays for use in comparative genomic hybridization (CGH) for cancer research, Agilent said today.


Agilent said that the collaboration will speed its development of commercial CGH microarrays, which could be used to screen tumors for genetic changes. Array-based CGH methods that "pinpoint the precise boundaries" of these changes "are not widely available today," the company said.


Agilent Laboratories, the central research facility of Agilent Technologies, is collaborating with TGen to "benchmark and optimize" the CGH arrays, which TGen is using under an early-access agreement, the company said.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.